13 February 2022 in New Phytologist
Summary: Tomato varieties resistant to the bacterial wilt pathogen Ralstonia solanacearum have the ability to restrict bacterial movement in the plant. Inducible vascular cell wall reinforcements seem to play a key role in confining R. solanacearum into the xylem vasculature of resistant tomato. However, the type of compounds involved in such vascular physico‐chemical barriers remain understudied, while being a key component of resistance. Here we use a combination of histological and live‐imaging techniques, together with spectroscopy and gene expression analysis to understand the nature of R. solanacearum‐induced formation of vascular coatings in resistant tomato. We describe that resistant tomato specifically responds to infection by assembling a vascular structural barrier formed by a ligno‐suberin coating and tyramine‐derived hydroxycinnamic acid amides. Further, we show that overexpressing genes of the ligno‐suberin pathway in a commercial susceptible variety of tomato restricts R. solanacearum movement inside the plant and slows disease progression, enhancing resistance to the pathogen. We propose that the induced barrier in resistant plants does not only restrict the movement of the pathogen, but may also prevent cell wall degradation by the pathogen and confer anti‐microbial properties, effectively contributing to resistance.
21 June 2023 in ACS Applied Bio Materials
The low endogenous regenerative capacity of the heart, added to the prevalence of cardiovascular diseases, triggered the advent of cardiac tissue engineering in the last decades. The myocardial niche plays a critical role in directing the function and fate of cardiomyocytes; therefore, engineering a biomimetic scaffold holds excellent promise. We produced an electroconductive cardiac patch of bacterial nanocellulose (BC) with polypyrrole nanoparticles (Ppy NPs) to mimic the natural myocardial microenvironment. BC offers a 3D interconnected fiber structure with high flexibility, which is ideal for hosting Ppy nanoparticles. BC-Ppy composites were produced by decorating the network of BC fibers (65 ± 12 nm) with conductive Ppy nanoparticles (83 ± 8 nm). Ppy NPs effectively augment the conductivity, surface roughness, and thickness of BC composites despite reducing scaffolds' transparency. BC-Ppy composites were flexible (up to 10 mM Ppy), maintained their intricate 3D extracellular matrix-like mesh structure in all Ppy concentrations tested, and displayed electrical conductivities in the range of native cardiac tissue. Furthermore, these materials exhibit tensile strength, surface roughness, and wettability values appropriate for their final use as cardiac patches. In vitro experiments with cardiac fibroblasts and H9c2 cells confirmed the exceptional biocompatibility of BC-Ppy composites. BC-Ppy scaffolds improved cell viability and attachment, promoting a desirable cardiomyoblast morphology. Biochemical analyses revealed that H9c2 cells showed different cardiomyocyte phenotypes and distinct levels of maturity depending on the amount of Ppy in the substrate used. Specifically, the employment of BC-Ppy composites drives partial H9c2 differentiation toward a cardiomyocyte-like phenotype. The scaffolds increase the expression of functional cardiac markers in H9c2 cells, indicative of a higher differentiation efficiency, which is not observed with plain BC. Our results highlight the remarkable potential use of BC-Ppy scaffolds as a cardiac patch in tissue regenerative therapies.
25 August 2023 in ACS Nano
Experimental studies and clinical trials of nanoparticles for treating diseases are increasing continuously. However, the reach to the market does not correlate with these efforts due to the enormous cost, several years of development, and off-target effects like cardiotoxicity. Multicellular organisms such as the Caenorhabditis elegans (C. elegans) can bridge the gap between in vitro and vertebrate testing as they can provide extensive information on systemic toxicity and specific harmful effects through facile experimentation following 3R EU directives on animal use. Since the nematodes' pharynx shares similarities with the human heart, we assessed the general and pharyngeal effects of drugs and polypyrrole nanoparticles (Ppy NPs) using C. elegans. The evaluation of FDA-approved drugs, such as Propranolol and Racepinephrine reproduced the arrhythmic behavior reported in humans and supported the use of this small animal model. Consequently, Ppy NPs were evaluated due to their research interest in cardiac arrhythmia treatments. The NPs' biocompatibility was confirmed by assessing survival, growth and development, reproduction, and transgenerational toxicity in C. elegans. Interestingly, the NPs increased the pharyngeal pumping rate of C. elegans in two slow-pumping mutant strains, JD21 and DA464. Moreover, the NPs increased the pumping rate over time, which sustained up to a day post-excretion. By measuring pharyngeal calcium levels, we found that the impact of Ppy NPs on the pumping rate could be mediated through calcium signaling. Thus, evaluating arrhythmic effects in C. elegans offers a simple system to test drugs and nanoparticles, as elucidated through Ppy NPs.
5 November 2025 in Advanced Healthcare Materials
Cardiac arrhythmia (CA), characterized by irregular heart rhythms, affects nearly 90% of individuals with cardiovascular diseases. Commonly triggered by myocardial infarction (MI) or ion channel dysfunctions, CA is traditionally treated using pacemakers, cardioversion, ablation, and anti‐arrhythmic drugs. Recently, emerging strategies like cardiac patches and injectable formulations with conductive nanomaterials (CNMs) have shown promise in restoring cardiac rhythm post‐MI. This review explores CNMs—such as gold nanoparticles, carbon nanotubes, and conjugated polymers—that mimic the electrical and mechanical properties of native cardiac tissue. While in vitro studies show encouraging results, translating CNMs to clinical settings faces challenges. Few studies have assessed their safety and efficacy in rodent models, and none in larger animals. This gap stems from the complexity and ethical hurdles of large animal research. To address this, the review advocates using small animal models like zebrafish, Drosophila melanogaster, and Caenorhabditis elegans . These models offer insights into pharmacokinetics, pharmacodynamics, genetic effects, and cardiac parameters such as ejection fraction and cardiac output—data often unattainable in vitro. Such platforms can better evaluate CNMs' safety and efficacy than 2D/3D cultures, accelerating progress toward clinical application.
16 July 2022 in New Phytologist